- Home
- PKG vs RVMD Comparison
PKG vs RVMD Comparison
Compare PKG & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKG | RVMD |
|---|---|---|
| Founded | 1867 | 2014 |
| Country | United States | United States |
| Employees | 13600 | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 15.2B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | PKG | RVMD |
|---|---|---|
| Price | $222.43 | $98.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $238.00 | $114.63 |
| AVG Volume (30 Days) | 881.2K | ★ 1.6M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.58 | N/A |
| Revenue | ★ $8,989,300,000.00 | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $4.70 | $552.08 |
| P/E Ratio | $26.39 | ★ N/A |
| Revenue Growth | ★ 7.23 | N/A |
| 52 Week Low | $172.72 | $29.17 |
| 52 Week High | $249.51 | $124.49 |
Technical Indicators
Market Signals| Indicator | PKG | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 45.91 |
| Support Level | $214.64 | $93.59 |
| Resistance Level | $249.51 | $107.45 |
| Average True Range (ATR) | 6.02 | 3.87 |
| MACD | -2.04 | -0.40 |
| Stochastic Oscillator | 14.15 | 26.64 |
Price Performance
Historical ComparisonAbout PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.